Journal Mobile Options
Table of Contents
Vol. 61, No. 1, 2012
Issue release date: August 2012

Effects of Xylitol on Blood Glucose, Glucose Tolerance, Serum Insulin and Lipid Profile in a Type 2 Diabetes Model of Rats

Islam M.S. · Indrajit M.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background/Aims: The present study was conducted to examine the antidiabetic effects of xylitol in a type 2 diabetes rat model. Methods: Six-week-old male Sprague-Dawley rats were randomly divided into 3 groups: normal control (NC), diabetic control (DBC) and xylitol (XYL). Diabetes was induced only in the DBC and XYL animal groups by feeding them a 10% fructose solution for 2 weeks followed by an injection (i.p.) of streptozotocin (40 mg/kg body weight). One week after the streptozotocin injection, the animals with a nonfasting blood glucose level of >300 mg/dl were considered to be diabetic. The XYL group was fed further with a 10% xylitol solution, whereas the NC and DBC groups were supplied with normal drinking water. Results: After 5 weeks of intervention, food and fluid intake, body weight, blood glucose, serum fructosamine and most of the serum lipids were significantly decreased, and serum insulin concentration and glucose tolerance ability was significantly increased in the XYL group compared to the DBC group. Liver weight, liver glycogen and serum triglycerides were not influenced by feeding with xylitol. Conclusion: The data of this study suggest that xylitol can be used not only as a sugar substitute but also as a supplement to antidiabetic food and other food products.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Bell W, Clapp R, Davis D, Epstein S, Farber E, Fox DA, Holub B, Jacobson MF, Linjinsky W, Millstone E, Reuber MD, Suzuki D, Temple NJ: Carcinogenicity of saccharin in laboratory animals and humans: letter to Dr. Harry Conacher of Health Canada. Int J Occup Environ Health 2002;8:387–393.
  2. Cohen S: What’s the truth about the health risks of sugar substitutes such as saccharin and aspartame? Health News 2001;7:10.
  3. Cohen SM, Garland EM, Cano M, St John MK, Khachab M, Wehner JM, Arnold LL: Effects of sodium ascorbate, sodium saccharin and ammonium chloride on the male rat urinary bladder. Carcinogenesis 1995;16:2743–2750.
  4. Bosetti C, Gallus S, Talamini R, Montella M, Franceschi S, Negri E, La Vecchia C: Artificial sweeteners and the risk of gastric, pancreatic, and endometrial cancers in Italy. Cancer Epidemiol Biomerkers Prev 2009;18:2235–2238.
  5. Ciappuccini R, Ansemant T, Maillefert JF, Tavernier C, Ornetti P: Aspartame-induced fibromyalgia, an unusual but curable cause of chronic pain. Clin Exp Rheumatol 2010;28:S131–S133.
  6. Davis DL, Ganter L, Weinkle J: Aspartame and incidence of brain malignancies. Cancer Epidemiol Biomerkers Prev 2008;17:1295–1296.

    External Resources

  7. Abhilash M, Paul MV, Varghese MV, Nair RH: Effect of long term intake of aspartame on antioxidant defense status in liver. Food Chem Toxicol 2011;49:1203–1207.
  8. Whitehouse CR, Boullata J, McCauley LA: The potential toxicity of artificial sweeteners. AAOHN J 2008;56:251–259.

    External Resources

  9. Abergaz EG: Aspartame not linked to cancer. Environ Health Perspect 2007;115:A16–A17.

    External Resources

  10. Huff J, LaDou J: Aspartame bioassay findings portend human cancer hazards. Int J Occup Environ Health 2007;13:446–448.

    External Resources

  11. Kroger M, Meister K, Kava R: Low calorie sweeteners and other sugar substitutes: a review of the safety issues. Compr Rev Food Sci Food Safety 2006;5:35–47.
  12. Jacob SE, Stechschulte S: Formaldehyde, aspartame, and migraines: a possible connection. Dermatitis 2008;19:E10–E11.
  13. Gilli G, Schiliro T, Traversi D, Piqnata C, Cordara S, Carraro E: Formaldehyde adduct to human serum albumin with reference to aspartame intake. Environ Toxicol Pharmacol 2008;25:89–93.
  14. Brown RJ, de Banate MA, Rother KI: Artificial sweeteners: a systematic review of metabolic effects in youth. Int J Pediatr Obes 2010;5:305–312.

    External Resources

  15. Brusick D, Borzelleca JF, Gallo M, Williams G, Kille J, Wallace Hayes A, Zavier Pi-Sunyer F, Willams C, Bruks W: Expert panel report on study of Splenda in male rats. Regul Toxicol Pharmacol 2009;55:6–12.
  16. Qin X: What made Canada become a country with the highest incidence of inflammatory bowel disease: could sucralose be the culprit? Can J Gastroenterol 2011;25:511.

    External Resources

  17. Abou-Donia MB, El-Masry Em, Abdel-Rahman AA, McLendon RE, Schiffman SS: Splenda alters gut microflora and increases intestinal P-glycoprotein and cytochrome P-450 in male rats. J Toxicol Environ Health A 2008;71:1415–1429.
  18. Grotoz VL: Sucralose and migraine. Headache 2008;48:164–165.

    External Resources

  19. Hirsch AR: Migraine triggered by sucralose – a case report. Headache 2007;47:447.

    External Resources

  20. Patel RM, Sarma R, Grimsley E: Popular sweetener sucralose as a migraine trigger. Headache 2006;46:1303–1304.

    External Resources

  21. Bigal ME, Krymchantowski AV: Migraine triggered by sucralose – a case report. Headache 2006;46:515–517.

    External Resources

  22. Gortz VL, Munro IC: An overview of the safety of sucralose. Regul Toxicol Pharmacol 2009;55:1–5.

    External Resources

  23. Bandyopadhyay A, Ghoshal S, Mukherjee A: Genotoxicity testing of low-calorie sweeteners: aspartame, acesulfame-K, and saccharin. Drug Chem Toxicol 2008;31:447–457.
  24. Karstadt M: Inadequate toxicity tests of food additive acesulfame. Int J Occup Envoiron Health 2010;16:89–96.
  25. Stanhope KL: Role of fructose-containing sugars in the epidemics of obesity and metabolic syndrome. Annu Rev Med 2011;63:329–343.

    External Resources

  26. Islam MS: Effects of xylitol as a sugar substitute on diabetes related parameters in nondiabetic rats. J Med Food 2011;14:505–511.
  27. Makinen KK: Sugar alcohol sweeteners as alternatives to sugar with special consideration of xylitol. Med Princ Pract 2011;20:303–320.
  28. Amo K, Arai H, Uebanso T, Fukaya M, Koganei M, Sasaki H, Yamamoto H, Taketani Y, Takeda E: Effects of xylitol on metabolic parameters and visceral fat accumulation. J Clin Biochem Nutr 2011;49:1–7.
  29. Mattila PT, Knuuttila MLE, Svanberg MJ: Dietary xylitol supplementation prevents osteoporotic changes in streptozotocin-diabetic rats. Metabolism 1998;47:578–583.
  30. Knuuttila ML, Kuoksa TH, Svanberg MJ, Mattila PT, Karjalainen KM, Kolehmainen E: Effects of dietary xylitol on collagen content and glycosylation in healthy and diabetic rats. Life Sci 2000;67:283–290.
  31. DeFronzo RA: Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview. Diabetologia 1992;35:389–397.
  32. Lo S, Russell JC, Taylor AW: Determination of glycogen in small tissue samples. J App Physiol 1970;28:234–236.
  33. Shafer RB, Levine AS, Marlette JM, Morley JE: Effects of xylitol on gastric emptying and food intake. Am J Clin Nutr 1987;45:744–747.
  34. Salminen E, Salminen S, Porkka L, Koivistoinen P: The effects of xylitol on gastric emptying and secretion on gastric inhibitory polypeptide in the rat. J Nutr 1984;114:2201–2203.
  35. Salminen EK, Salminen SJ, Porkka L, Kwasowski P, Marks V, Koivistoinen PE: Xylitol vs glucose: effect on the rate of gastric emptying and motilin, insulin, and gastric inhibitory polypeptide release. Am J Clin Nutr 1989;49:1228–1232.
  36. Livesey G: Health potential of polyols as sugar replacers, with emphasis on low glycemic properties. Nutr Res Rev 2003;16:163–191.
  37. Salminen S, Salminen E, Marks V: The effects of xylitol on the secretion of insulin and gastrin inhibitory polypeptide in man and rats. Diabetologia 1982;22:480–482.
  38. Muller-Hess R, Geser CA, Bonjour JP, Jequier E, Felber JP: Effects of oral xylitol administration on carbohydrate and lipid metabolism in normal subjects. Infusionsther Klin Ernahr 1975;2:247–252.
  39. Ferreira LDMCB, Brau L, Nikolovski S, Raja G, Palmer TN, Fournier PA: Effect of streptozotocin-induced diabetes on glycogen resyntehsis in fasted rats post-high-intensity exercise. Am J Physil Endocrinol Metabol 2001;280:E83–E91.
  40. Otto C, Sonnichsen AC, Titter MM, Ritter MM, Richter WO, Schwandt P: Influence of fiber, xylitol and fructose in enteral formulas on glucose and lipid metabolism in normal subjects. Clin Investig 1993;71:290–293.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50